» Articles » PMID: 8093350

Role and Mutational Heterogeneity of the P53 Gene in Hepatocellular Carcinoma

Overview
Journal Cancer Res
Specialty Oncology
Date 1993 Jan 15
PMID 8093350
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The mutational spectrum of the p53 gene was analyzed in 53 hepatocellular carcinomas. Somatic mutations of the p53 gene were detected in 17 cases (32%). Among these 17 mutations, 9 were missense mutations; the mutations in the other 8 cases were nonsense mutations, deletions, or mutations at the intron-exon junctions. These mutations were found in a wide region stretching from exon 4 to exon 10 without any single mutational hot spot. G:C to T:A transversions were predominant, suggesting the involvement of environmental mutagens in the mutagenesis of the p53 gene in a subset of the hepatocellular carcinoma cases. Mutations of the p53 gene occurred frequently in advanced tumors, although several tumors in the early stages also showed mutations. A deletion map of chromosome 17 was constructed by using 10 polymorphic probes and was compared with the p53 gene mutation in each case. Loss of heterozygosity (LOH) on chromosome 17p was observed in 49% of the cases (24 of 49), and two commonly deleted regions were detected (around the p53 locus and at 17p13.3 to the telomere). Sixteen of the 17 cases with p53 gene mutations showed LOH around the p53 locus, and mutations were rare in hepatocellular carcinomas without LOH. However, no mutations were detected in 8 cases with LOH on 17p, suggesting the possibility that an unidentified tumor suppressor gene(s) located on 17p may have also been involved in hepatocarcinogenesis.

Citing Articles

Identification and validation of a prognostic-related mutant gene for hepatocellular carcinoma.

Song Z, Song X, Li H, Cheng Z, Mo Z, Yang X Front Immunol. 2023; 14:1236995.

PMID: 38022557 PMC: 10630911. DOI: 10.3389/fimmu.2023.1236995.


Role of p53 suppression in the pathogenesis of hepatocellular carcinoma.

Choudhary H, Mandlik S, Mandlik D World J Gastrointest Pathophysiol. 2023; 14(3):46-70.

PMID: 37304923 PMC: 10251250. DOI: 10.4291/wjgp.v14.i3.46.


Gain-of-Function p53N236S Mutation Drives the Bypassing of HRas-Induced Cellular Senescence via PGC-1α.

Yang H, Zhang K, Guo Y, Guo X, Hou K, Hou J Int J Mol Sci. 2023; 24(4).

PMID: 36835200 PMC: 9960896. DOI: 10.3390/ijms24043790.


Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma.

Song Z, Yu Y, Zhang G, Li S Front Cell Dev Biol. 2021; 9:728574.

PMID: 34676211 PMC: 8523793. DOI: 10.3389/fcell.2021.728574.


Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma.

Nishida N, Kudo M Cancers (Basel). 2020; 12(5).

PMID: 32443599 PMC: 7281618. DOI: 10.3390/cancers12051274.